Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
Rhea-AI Summary
Harrow (Nasdaq: HROW) will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 AM ET in Miami, Florida. The management presentation will be webcast live on the company website, with a replay available for approximately 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – HROW
In the Mar 4 session, HROW gained 1.59%, reflecting a mild positive market reaction. Argus tracked a trough of -10.3% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Phase 3 trial plan | Positive | -28.0% | FDA cleared IND for Phase 3 TRIESENCE trial in cataract surgery setting. |
| Mar 02 | Earnings and guidance | Positive | -28.0% | Reported record Q4 and 2025 revenue with 2026 revenue and EBITDA guidance. |
| Feb 18 | Earnings date notice | Neutral | -1.3% | Announced timing of Q4 and year-end 2025 results and conference call. |
| Feb 17 | Product launch news | Positive | +6.0% | Launched PharmaPack cash-pay kits as FDA-approved ophthalmic alternatives. |
| Feb 03 | Competitive positioning | Positive | +5.1% | OSRX confirmed ongoing licensing and availability of compounded ophthalmic meds. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news-linked moves show large negative reactions to major clinical and earnings updates, while product and competitive positioning news saw moderate gains.
Over recent months, Harrow reported several milestones. On Mar 2, 2026, it announced record Q4 and full-year 2025 results with 2026 guidance, followed by a -27.96% reaction. On Mar 3, 2026, it received FDA clearance for a Phase 3 TRIESENCE® trial, again paired with a -27.96% move. Earlier, product initiatives like PharmaPack (Feb 17, 2026) and OSRX licensing news (Feb 3, 2026) coincided with gains near 5–6%. Today’s conference appearance fits into an active investor-relations cadence following these fundamental updates.
Key Terms
ophthalmic medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida.
The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.
Contact:
Mike Biega, Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890
